These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 22916799)
21. Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia. Kilic U; Yilmaz B; Ugur M; Yüksel A; Reiter RJ; Hermann DM; Kilic E J Pineal Res; 2012 Mar; 52(2):228-35. PubMed ID: 21913972 [TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives as novel melatonin receptor ligands. Li G; Zhou H; Jiang Y; Keim H; Topiol SW; Poda SB; Ren Y; Chandrasena G; Doller D Bioorg Med Chem Lett; 2011 Feb; 21(4):1236-42. PubMed ID: 21237644 [TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and pharmacological effects of structurally simple ligands for MT(1) and MT(2) melatonin receptors. Carocci A; Catalano A; Lovece A; Lentini G; Duranti A; Lucini V; Pannacci M; Scaglione F; Franchini C Bioorg Med Chem; 2010 Sep; 18(17):6496-511. PubMed ID: 20674373 [TBL] [Abstract][Full Text] [Related]
24. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. Audinot V; Bonnaud A; Grandcolas L; Rodriguez M; Nagel N; Galizzi JP; Balik A; Messager S; Hazlerigg DG; Barrett P; Delagrange P; Boutin JA Biochem Pharmacol; 2008 May; 75(10):2007-19. PubMed ID: 18384758 [TBL] [Abstract][Full Text] [Related]
25. Melatonin receptor agonist ramelteon activates the extracellular signal-regulated kinase 1/2 in mouse cerebellar granule cells. Imbesi M; Uz T; Manev H Neuroscience; 2008 Sep; 155(4):1160-4. PubMed ID: 18664376 [TBL] [Abstract][Full Text] [Related]
26. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity. Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992 [TBL] [Abstract][Full Text] [Related]
27. Ramelteon: TAK 375. Drugs R D; 2005; 6(3):186-8. PubMed ID: 15869323 [TBL] [Abstract][Full Text] [Related]
29. Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. Greenblatt DJ; Harmatz JS; Karim A J Clin Pharmacol; 2007 Apr; 47(4):485-96. PubMed ID: 17389558 [TBL] [Abstract][Full Text] [Related]
30. Pharmacological characterization of M-II, the major human metabolite of ramelteon. Nishiyama K; Nishikawa H; Kato K; Miyamoto M; Tsukamoto T; Hirai K Pharmacology; 2014; 93(3-4):197-201. PubMed ID: 24923230 [TBL] [Abstract][Full Text] [Related]
31. Development of substituted N-[3-(3-methoxylphenyl)propyl] amides as MT(2)-selective melatonin agonists: improving metabolic stability. Hu Y; Zhu J; Chan KH; Wong YH Bioorg Med Chem; 2013 Jan; 21(2):547-52. PubMed ID: 23228808 [TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT Duroux R; Rami M; Landagaray E; Ettaoussi M; Caignard DH; Delagrange P; Melnyk P; Yous S Eur J Med Chem; 2017 Dec; 141():552-566. PubMed ID: 29102176 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014). Rivara S; Pala D; Bedini A; Spadoni G Expert Opin Ther Pat; 2015 Apr; 25(4):425-41. PubMed ID: 25579320 [TBL] [Abstract][Full Text] [Related]
35. Circadian system functionality, hippocampal oxidative stress, and spatial memory in the APPswe/PS1dE9 transgenic model of Alzheimer disease: effects of melatonin or ramelteon. Baño Otalora B; Popovic N; Gambini J; Popovic M; Viña J; Bonet-Costa V; Reiter RJ; Camello PJ; Rol MÁ; Madrid JA Chronobiol Int; 2012 Aug; 29(7):822-34. PubMed ID: 22823866 [TBL] [Abstract][Full Text] [Related]
36. Ramelteon, a selective MT1/MT2 receptor agonist, suppresses the proliferation and invasiveness of endometrial cancer cells. Osanai K; Kobayashi Y; Otsu M; Izawa T; Sakai K; Iwashita M Hum Cell; 2017 Jul; 30(3):209-215. PubMed ID: 28382516 [TBL] [Abstract][Full Text] [Related]
37. N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands. Rivara S; Vacondio F; Fioni A; Silva C; Carmi C; Mor M; Lucini V; Pannacci M; Caronno A; Scaglione F; Gobbi G; Spadoni G; Bedini A; Orlando P; Lucarini S; Tarzia G ChemMedChem; 2009 Oct; 4(10):1746-55. PubMed ID: 19728346 [TBL] [Abstract][Full Text] [Related]
38. A Case of Unilateral Hypnic Headache: Rapid Response to Ramelteon, a Selective Melatonin MT1/MT2 Receptor Agonist. Arai M Headache; 2015; 55(7):1010-1. PubMed ID: 26121162 [No Abstract] [Full Text] [Related]
39. Melatonin and Synthetic Melatoninergic Agonists in Psychiatric and Age-associated Disorders: Successful and Unsuccessful Approaches. Hardeland R Curr Pharm Des; 2016; 22(8):1086-101. PubMed ID: 25248806 [TBL] [Abstract][Full Text] [Related]
40. Photoperiodic regulation of MT1 and MT2 melatonin receptor expression in spleen and thymus of a tropical rodent Funambulus pennanti during reproductively active and inactive phases. Ahmad R; Haldar C Chronobiol Int; 2010 May; 27(3):446-62. PubMed ID: 20524795 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]